BridgeBio Pharma Inc reports results for the quarter ended March 31 - Earnings Summary
29/04/2025 22:00
BridgeBio Pharma Inc BBIO.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -20 cents. The mean expectation of thirteen analysts for the quarter was for a loss of 92 cents per share. Wall Street expected results to range from $-1.28 to -57 cents per share. Revenue fell 44.8% to $116.63 million from a year ago; analysts expected $61.94 million. BridgeBio Pharma Inc's reported EPS for the quarter was a loss of 88 cents. The company reported a quarterly loss of $167.42 million. BridgeBio Pharma Inc shares had risen by 3.8% this quarter and gained 30.8% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 5.2% in the last three months. In the last 30 days, four analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for BridgeBio Pharma Inc is $53.00 This summary was machine generated from LSEG data April 29 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.92 | -0.88 | Beat |
| Dec. 31 2024 | -1.13 | -1.40 | Missed |
| Sep. 30 2024 | -0.98 | -1.10 | Missed |
| Jun. 30 2024 | -1.06 | -0.39 | Beat |
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels